TOKYO - Japan's health ministry on Monday approved the manufacture and sale of a drug for Alzheimer's disease developed by Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc., paving the way for the drug to be made available for use within the year.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
